Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Interest Expenses (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Interest Expenses for 4 consecutive years, with $16.4 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 11.69% to $16.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $68.1 million through Dec 2025, down 5.41% year-over-year, with the annual reading at $68.1 million for FY2025, 5.41% down from the prior year.
  • Interest Expenses for Q4 2025 was $16.4 million at Phathom Pharmaceuticals, up from $16.1 million in the prior quarter.
  • The five-year high for Interest Expenses was $18.6 million in Q4 2024, with the low at $2.8 million in Q1 2022.
  • Average Interest Expenses over 4 years is $13.1 million, with a median of $14.6 million recorded in 2023.
  • The sharpest move saw Interest Expenses surged 234.07% in 2023, then dropped 12.85% in 2025.
  • Over 4 years, Interest Expenses stood at $9.6 million in 2022, then soared by 35.69% to $13.0 million in 2023, then skyrocketed by 42.7% to $18.6 million in 2024, then dropped by 11.69% to $16.4 million in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $16.4 million, $16.1 million, and $17.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.